Zelgen(SH:688266) 2 1 Shi Ji Jing Ji Bao Dao·2025-07-01 03:53Group 1 - A-shares showed mixed performance in early trading on July 1, with the innovative drug sector leading in gains [1] - A500 ETF by Jiashi (159351) experienced a net inflow of over 10.5 billion yuan yesterday, accumulating over 20 billion yuan in the last two trading days, ranking first among similar products [1] - The A500 ETF has seen its share increase by 48.12 billion yuan year-to-date, also ranking first among similar products [1] Group 2 - The two departments issued measures to support the high-quality development of innovative drugs, emphasizing the use of medical insurance data for drug research and development [2] - East China Securities views innovative drugs as a core investment theme, suggesting to focus on "innovative drugs +" and companies with strong alpha in other sub-industries [2] - Global pharmaceutical investment and financing are recovering, positively impacting the CXO and upstream life sciences sectors, leading to an upward trend in orders and financial reports [2] Group 3 - Bohai Securities reported that all major indices were raised last week, with the ETF market seeing a net inflow of 13.94 billion yuan [3] - The average daily trading volume of the ETF market reached 3,113.22 billion yuan, with a daily turnover rate of 9.64% [3] - The CSI A500 index saw a significant inflow of over 7 billion yuan, with the banking, Hong Kong non-bank, and innovative drug sectors favored by investors [3]